SG11201402206YA - Morpholinyl benzotriazine for use in cancer therapy - Google Patents

Morpholinyl benzotriazine for use in cancer therapy

Info

Publication number
SG11201402206YA
SG11201402206YA SG11201402206YA SG11201402206YA SG11201402206YA SG 11201402206Y A SG11201402206Y A SG 11201402206YA SG 11201402206Y A SG11201402206Y A SG 11201402206YA SG 11201402206Y A SG11201402206Y A SG 11201402206YA SG 11201402206Y A SG11201402206Y A SG 11201402206YA
Authority
SG
Singapore
Prior art keywords
benzotriazine
morpholinyl
cancer therapy
cancer
therapy
Prior art date
Application number
SG11201402206YA
Other languages
English (en)
Inventor
Werner Mederski
Thomas Fuchss
Ulrich Emde
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201402206YA publication Critical patent/SG11201402206YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/10Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201402206YA 2011-11-18 2012-10-30 Morpholinyl benzotriazine for use in cancer therapy SG11201402206YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011118830A DE102011118830A1 (de) 2011-11-18 2011-11-18 Morpholinylbenzotriazine
PCT/EP2012/004542 WO2013072015A1 (de) 2011-11-18 2012-10-30 Morpholinylbenzotriazine zur anwendung in der krebstherapie

Publications (1)

Publication Number Publication Date
SG11201402206YA true SG11201402206YA (en) 2014-11-27

Family

ID=47143824

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402206YA SG11201402206YA (en) 2011-11-18 2012-10-30 Morpholinyl benzotriazine for use in cancer therapy

Country Status (24)

Country Link
US (1) US9187469B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2780332B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP6096792B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR20140097391A (US20070167479A1-20070719-C00034.png)
CN (1) CN103930408B (US20070167479A1-20070719-C00034.png)
AU (1) AU2012339196B2 (US20070167479A1-20070719-C00034.png)
BR (1) BR112014011805A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2856103C (US20070167479A1-20070719-C00034.png)
DE (1) DE102011118830A1 (US20070167479A1-20070719-C00034.png)
DK (1) DK2780332T3 (US20070167479A1-20070719-C00034.png)
EA (1) EA201400595A1 (US20070167479A1-20070719-C00034.png)
ES (1) ES2572605T3 (US20070167479A1-20070719-C00034.png)
HK (1) HK1199875A1 (US20070167479A1-20070719-C00034.png)
HR (1) HRP20160495T1 (US20070167479A1-20070719-C00034.png)
HU (1) HUE027577T2 (US20070167479A1-20070719-C00034.png)
IL (1) IL232577A (US20070167479A1-20070719-C00034.png)
IN (1) IN2014KN01287A (US20070167479A1-20070719-C00034.png)
MX (1) MX2014005838A (US20070167479A1-20070719-C00034.png)
PL (1) PL2780332T3 (US20070167479A1-20070719-C00034.png)
RS (1) RS54768B1 (US20070167479A1-20070719-C00034.png)
SG (1) SG11201402206YA (US20070167479A1-20070719-C00034.png)
SI (1) SI2780332T1 (US20070167479A1-20070719-C00034.png)
WO (1) WO2013072015A1 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201404438B (US20070167479A1-20070719-C00034.png)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2841428T (pt) 2012-04-24 2018-11-29 Vertex Pharma Inibidores de adn-pk
EP3985003B1 (en) 2013-03-12 2023-08-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
CN105814036B (zh) 2013-10-17 2018-10-26 沃泰克斯药物股份有限公司 作为dna-pk抑制剂的共晶
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법
CN107793373B (zh) * 2017-10-31 2019-09-17 广西师范大学 2-取代苯并三嗪酮衍生物及其制备方法
EA202091708A1 (ru) * 2018-01-17 2020-11-10 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
WO2021083936A1 (en) 2019-11-01 2021-05-06 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds
WO2022268648A1 (en) 2021-06-24 2022-12-29 Syngenta Crop Protection Ag 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides
WO2023247360A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9190155U1 (de) 1990-11-06 1993-10-07 Pfizer Inc., New York, N.Y. Chinazolinderivate zur Steigerung der Antitumoraktivität
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
AU2001288432A1 (en) * 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
US7291733B2 (en) * 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
CN101230045B (zh) * 2008-02-14 2013-04-10 沈阳药科大学 芳环并三嗪类衍生物及其应用
SG183855A1 (en) * 2010-03-16 2012-10-30 Merck Patent Gmbh Morpholinylquinazolines

Also Published As

Publication number Publication date
HUE027577T2 (en) 2016-10-28
MX2014005838A (es) 2014-07-30
DK2780332T3 (en) 2016-05-30
JP6096792B2 (ja) 2017-03-15
RS54768B1 (sr) 2016-10-31
ES2572605T3 (es) 2016-06-01
CN103930408A (zh) 2014-07-16
ZA201404438B (en) 2015-12-23
KR20140097391A (ko) 2014-08-06
AU2012339196B2 (en) 2017-04-27
US9187469B2 (en) 2015-11-17
JP2015502926A (ja) 2015-01-29
HK1199875A1 (en) 2015-07-24
IN2014KN01287A (US20070167479A1-20070719-C00034.png) 2015-10-16
HRP20160495T1 (hr) 2016-06-03
CA2856103A1 (en) 2013-05-23
EP2780332A1 (de) 2014-09-24
PL2780332T3 (pl) 2016-07-29
CN103930408B (zh) 2016-09-07
EP2780332B1 (de) 2016-02-24
DE102011118830A1 (de) 2013-05-23
IL232577A0 (en) 2014-06-30
WO2013072015A1 (de) 2013-05-23
EA201400595A1 (ru) 2014-11-28
US20140275072A1 (en) 2014-09-18
SI2780332T1 (sl) 2016-06-30
AU2012339196A1 (en) 2014-07-03
CA2856103C (en) 2020-08-25
BR112014011805A2 (pt) 2017-05-16
IL232577A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
IL289300A (en) Combined treatment for cancer
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
HK1199875A1 (en) Morpholinyl benzotriazine for use in cancer therapy
HK1198133A1 (en) Crizotinib for use in the treatment of cancer
HUE048876T2 (hu) Rákos megbetegedések kezelése
EP2807180A4 (en) PEPTIDE AGENTS USED IN ANTICANCER THERAPY
IL227558A0 (en) A therapeutic agent for tumors
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
HK1201301A1 (en) Erbb3 mutations in cancer erbb3
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
EP2585115A4 (en) ANTICANCER TREATMENT
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
GB201106630D0 (en) Cancer therapy
IL239231A0 (en) Combined cancer treatment
AU2012900259A0 (en) Agents for use in cancer therapy
GB201118220D0 (en) Cancer therapy
GB201020513D0 (en) Cancer therapy
GB201109133D0 (en) Photodynamic therapy